A potent, selective, orally bioavailable, covalent Bruton's tyrosine kinase (Btk) inhibitor with potential antineoplastic activity (IC50 value 1400 selective over a number of Src family kinases and B cell signaling components in full length recombinant Btk protein assay). More specific for BTK than PCI 32765 (Ibrutinib, Axon 1858) is, and with a shorter half-life.
AVL 292 reduces migration of CLL cells towards CXCL12 and CXCL13, and reduces viability as well as markers of BCR activation, such as CCL3 and CCL4 chemokine production, in primary CLL cells cultured with Nurse-like Cells (NLC).